A pioneering international consortium led by the University of Southampton has secured a substantial £3.8 million grant from the prestigious Horizon Europe Marie Skłodowska-Curie Actions (MSCA) programme to revolutionize treatments for cancer and chronic inflammation. This ambitious initiative merges the expertise of ten academic research groups, four innovative companies, a hospital, and a non-profit organisation, forming a formidable alliance across Europe dedicated to advancing next-generation therapeutics based on oligonucleotide technology.
Oligonucleotides (ONs), short synthetic strands of nucleotides—the fundamental units of DNA and RNA—are rapidly emerging as groundbreaking agents in molecular medicine. Unlike conventional drugs that often target downstream symptoms, ONs intervene at the genetic level by delivering precise molecular instructions that modulate gene expression. By selectively binding to RNA, these molecules can inhibit the production of deleterious proteins directly responsible for pathological conditions such as cancer and chronic inflammatory diseases, thus halting disease progression at its root.
Despite their revolutionary potential, oligonucleotide therapies face critical challenges that hinder their widespread clinical adoption. Chief among these are their inherent instability within biological systems, making them susceptible to rapid degradation by nucleases in the bloodstream. Additionally, achieving effective and targeted delivery to the appropriate cell types remains difficult due to physiological barriers. Compounding these issues, off-target effects and immune system activation sometimes cause adverse reactions. The new ON-TRACT project is laser-focused on overcoming these hurdles by developing novel stabilization methods, optimized delivery vehicles, and safety-enhancing formulations.
The ON-TRACT consortium’s multi-disciplinary approach leverages expertise from synthetic chemistry, chemical engineering, molecular biology, and clinical sciences to develop robust oligonucleotide platforms capable of precise targeting and sustained activity. Advanced chemical modifications of the oligonucleotide backbone and sugar-phosphate moieties are being engineered to enhance nuclease resistance while preserving or improving hybridization affinity for target RNA sequences. These semi-synthetic nucleic acid analogues aim to prolong therapeutic half-life and reduce immunogenicity.
Efficient intracellular delivery is another cornerstone of the ON-TRACT research agenda. The project explores innovative carriers such as lipid nanoparticles, conjugated peptides, and polymer-based nanoparticles that can navigate the complex cellular microenvironment. These vectors are designed to facilitate the endosomal escape of ONs, ensuring their bioavailability within the cytoplasm or nucleus where gene regulation occurs. Researchers are carefully tuning the physicochemical properties of these carriers to optimize biodistribution and minimize off-target interactions or toxicity.
A particularly transformative dimension of ON-TRACT is its commitment to sustainability and ethical experimentation. Rather than relying on animal models, the project adopts cutting-edge organoid technology, cultivating three-dimensional mini-organs from patient-derived stem cells. These organoids faithfully recapitulate human tissue architecture and function, enabling high fidelity preclinical assessment of oligonucleotide efficacy and safety. This paradigm not only accelerates translational research but also aligns with evolving regulatory and ethical standards prioritizing reduction of animal use.
Training the next generation of life science innovators is integral to the ON-TRACT endeavour. Fourteen doctoral candidates distributed across academic, industrial, and clinical partner institutions in multiple European countries—including the UK, Sweden, France, Poland, Belgium, and Italy—will receive rigorous interdisciplinary education. Their research projects will span fundamental nucleic acid chemistry, formulation science, delivery system engineering, and translational oncology, preparing them to be leaders in the burgeoning fields of nucleic acid therapeutics and precision medicine.
The therapeutic focus of ON-TRACT spans several critical diseases with high unmet medical need, including lung cancer, hematological malignancies such as blood cancers, and chronic inflammatory conditions. These complex diseases often elude existing drug modalities due to genetic heterogeneity and dynamic pathological mechanisms. By harnessing the molecular specificity of oligonucleotides, the project aims to tailor treatments that are not only highly effective but also minimize systemic toxicity, heralding a new era of personalized medicine.
The University of Southampton spearheads this effort, collaborating closely with distinguished partners such as the University of Cambridge, Karolinska Institute, AstraZeneca, Centre Nationale de la Recherche CNRS, and others, reflecting a robust European research network. Together, the consortium pools diverse expertise and cutting-edge technologies to push oligonucleotide science from the bench to bedside, addressing major challenges that have so far limited clinical impact.
This initiative complements Southampton’s involvement in the INT2ACT consortium, which focuses on nucleic acids (NAs) broadly as diagnostic and therapeutic tools. While INT2ACT advances nucleic acid applications across multiple disease spectra, ON-TRACT zeroes in on refining oligonucleotide stability, delivery, and safety specifically for cancer and chronic inflammation. This symbiotic relationship between projects amplifies scientific progress and accelerates pipeline development for nucleic-acid-based medicines.
The future envisioned by ON-TRACT could radically alter current paradigms in oncology and immunomodulation, providing patients with targeted treatments capable of rewiring their genetic circuitry. As oligonucleotide therapies gain traction, the promise of durable remissions, fewer side effects, and tailored therapeutic regimens becomes increasingly attainable. These advances are poised to reshape healthcare by aligning molecular precision with patient-specific biology.
In addition to their therapeutic promise, oligonucleotide technologies hold wider implications for sustainable pharmaceutical manufacturing. ON-TRACT explores greener synthesis methods to reduce environmental impact, including enzymatic synthesis and minimization of hazardous reagents. This sustainability focus aligns with global trends for eco-friendly drug production and responsible innovation, ensuring that progress benefits both health and planetary wellbeing.
In summary, the ON-TRACT project represents a bold and comprehensive effort to overcome longstanding barriers in oligonucleotide therapeutics. By integrating cutting-edge chemistry, advanced delivery science, ethical model systems, and extensive training initiatives, the consortium is laying the groundwork for transformative treatments for cancer and chronic inflammatory diseases. With its multisectoral European collaboration and visionary scientific agenda, ON-TRACT is positioned to accelerate the arrival of next-generation precision medicines that target the genetic origins of disease with unprecedented accuracy and safety.
Subject of Research: Development of next-generation oligonucleotide-based therapies for cancer and chronic inflammation, focusing on enhancing stability, delivery, and safety.
Article Title: Revolutionizing Cancer and Inflammation Treatment: The ON-TRACT Oligonucleotide Initiative
News Publication Date: Not specified
Web References:
Keywords: Cancer, Oncology, Cancer genomics, Inflammation, Blood cancer
